

22 **Abstract**

23 Reported COVID-19 cases and deaths provide a delayed and incomplete picture of SARS-CoV-2
24 infections in the United States (US). Accurate estimates of both the timing and magnitude of
25 infections are needed to characterize viral transmission dynamics and better understand COVID-
26 19 disease burden. We estimated time trends in SARS-CoV-2 transmission and other COVID-19
27 outcomes for every county in the US, from the first reported COVID-19 case in January 13, 2020
28 through January 1, 2021. To do so we employed a Bayesian modeling approach that
29 explicitly accounts for reporting delays and variation in case ascertainment, and generates daily
30 estimates of incident SARS-CoV-2 infections on the basis of reported COVID-19 cases and
31 deaths. The model is freely available as the *covidestim* R package. Nationally, we estimated there
32 had been 49 million symptomatic COVID-19 cases and 400,718 COVID-19 deaths by the end of
33 2020, and that 27% of the US population had been infected. The results also demonstrate wide
34 county-level variability in the timing and magnitude of incidence, with local epidemiological
35 trends differing substantially from state or regional averages, leading to large differences in the
36 estimated proportion of the population infected by the end of 2020. Our estimates of true
37 COVID-19 related deaths are consistent with independent estimates of excess mortality, and our
38 estimated trends in cumulative incidence of SARS-CoV-2 infection are consistent with trends in
39 seroprevalence estimates from available antibody testing studies. Reconstructing the underlying
40 incidence of SARS-CoV-2 infections across US counties allows for a more granular
41 understanding of disease trends and the potential impact of epidemiological drivers.

42

43 Introduction

44 The numbers of newly diagnosed cases and confirmed COVID-19 deaths are the most easily
45 observed measures of the health burden associated with COVID-19 and have been widely used
46 to track the trajectory of the epidemic at the national, state, and local level.^{1,2} However, there are
47 at least three limitations of using reported cases and deaths for this purpose. First, testing is
48 primarily organized to identify symptomatic individuals, but a large fraction of SARS-CoV-2
49 infections are asymptomatic,³ leading to case counts that are substantially smaller than the true
50 incidence of infection. Second, the degree to which case counts undercount infections is sensitive
51 to the availability and utilization of diagnostic testing, which has varied over time and
52 geography.^{4,5,6} For this reason, it can be difficult to distinguish true trends from changes in
53 testing practices. Third, case and death counts are lagging indicators of the transmission
54 dynamics of the pathogen, as they are affected by delays associated with the incubation period,
55 care-seeking behavior of symptomatic individuals, diagnostic processing times, and reporting
56 practices. Taken together, these limitations present challenges to analyses that rely on these
57 metrics as primary signals of SARS-CoV-2 spread.

58 A better indicator of changes in local transmission is the effective reproduction number (R_t),
59 which represents the average number of secondary infections caused by an individual infected at
60 some time t .⁷ R_t can signal short-term changes in transmission in response to policy and
61 behavioral changes. However, R_t is not a directly observable quantity and estimates of R_t based
62 on raw case reports become biased when reporting delays are incorrectly estimated,⁵ weakening
63 their usefulness as a measure of transmission.

64 Unbiased estimates of COVID-19 cases and the R_t of SARS-CoV-2 can provide more accurate
65 insight into the size and scope of the United States (US) epidemic and inform current and future
66 COVID-19 control policies. A number of modeling approaches have been developed to
67 reconstruct the time series of infections and deaths over the course of the US epidemic. These
68 approaches typically do not allow for variability in case ascertainment and infection fatality
69 ratios (IFRs) across space and time, nor do they attempt to model SARS-CoV-2 infections or
70 COVID-19 deaths at fine spatial scales, such as at the county level.^{8,9}

71 Here, we present detailed estimates of viral dynamics for all US states and counties, based on a
72 Bayesian statistical model that combines multiple data sources to estimate SARS-CoV-2
73 infection patterns from observed case notifications and death reports. We apply our model to
74 publicly available COVID-19 case and death data and report on the trajectory of the epidemic
75 from the first reported case (January 13, 2020) until January 1, 2021. The model is available on
76 GitHub (<https://github.com/covidestim/covidestim/>) as a package for the R programming
77 language (*covidestim*).

78 **Results**

79 **Analytic Overview**

80 We developed a mechanistic model to back-calculate SARS-CoV-2 infections and subsequent
81 outcomes based on reported COVID-19 cases and deaths. In this model the natural history of
82 COVID-19 is represented using four health states: asymptomatic or pre-symptomatic SARS-
83 CoV-2 infection (*Asymptomatic*), symptomatic but not severe COVID-19 disease (*Symptomatic*),
84 severe COVID-19 disease (*Severe*), and death from COVID-19 (*Death*). In each health state
85 (except *Death*) individuals either recover or transition to a more severe state after some delay.

86 Infected individuals can be diagnosed in the *Asymptomatic*, *Symptomatic*, or *Severe* states, and
87 we assume all diagnosed cases and all deaths among diagnosed individuals are reported after as
88 short delay. Figure 1 shows modeled health states and transitions. The model generates several
89 outcomes of epidemiological importance, including R_t , total infections, symptomatic cases, total
90 deaths, and case ascertainment; we estimated these outcomes for each US state and county from
91 the start of the epidemic until January 1, 2021.

92 **Figure 1:** A model schematic of the main health states: *Asymptomatic* (denoted
93 “Asymp.”), *Symptomatic* (denoted “Symp.”), *Severe*, and *Death*. The subscript “dx”
94 indicates that individuals in that state have received a diagnosis of COVID-19. Each
95 transition (denoted with an arrow) has an associated probability and delay distribution.
96 Solid arrows denote disease progression; dotted arrows denote recovery; short dashed
97 arrows denote diagnosis; long dashed arrows denote reporting. All diagnosed cases and
98 deaths are assumed to be reported after a given delay.

99

100 **Main Findings**

101 *Incidence and R_t*

102 The SARS-CoV-2 epidemic in the US consisted of a series of related outbreaks, which varied
103 greatly in both the intensity of transmission and the extent of geographic spread (Figure 2). The
104 March outbreak in New York State was the largest per population in a single state; on March 28,
105 we estimate that New York State had 812 (95% credible interval: 477, 1393) infections per
106 100,000, and 39% (23%, 68%) of all infections in the US on that day. Local surges in infections
107 during the fall and winter of 2020 rivaled New York’s March outbreak in scale, but occurred in

108 the context of a more generalized US epidemic. South Dakota, for example, had its highest per
109 capita infections of 2020 on November 7 (628 [405, 1009] infections per 100,000), but
110 accounted for just 1.2% (0.8%, 2.0%) of all US infections that day. Forty-five states experienced
111 the highest daily infections per capita in November or December (Figure 3).

112 **Figure 2:** Panels 1-10: County-level infections per 100,000 population per day at 10
113 timepoints between April 1, 2020 and January 1, 2021. Panel 11: Time series of national
114 SARS-CoV-2 infection estimates (orange line) and reported COVID-19 diagnoses (blue
115 bars) per 100,000 people per day from March 1, 2020 to January 1, 2021.

116 **Figure 3:** Incident infections per 100,000 residents per day for each US state from March
117 1, 2020 to January 1, 2021. Shaded areas represent 95% credible intervals.

118 While most states and counties had lower levels of transmission during the summer months, few
119 achieved established thresholds of low levels of community transmission, defined as fewer than
120 20 confirmed cases per 100,000 per week.¹⁰ We estimate that only six states (Alaska, Hawaii,
121 Montana, Oregon, Vermont, and West Virginia) had fewer than 20 symptomatic cases per
122 100,000 inhabitants per week after transmission was established locally. Notably, Vermont
123 remained below this threshold from the week of April 27 until the week of October 5.

124 Estimates of R_t at the start of the epidemic varied greatly by state. The median state-level
125 estimate of R_t on the first day a case was reported in each state was 4.9 (range: 2.0 [1.7 – 2.4] in
126 Washington to 11.4 [7.4– 18.9] in New York). Throughout April, R_t estimates dropped
127 substantially. Over the period May 1, 2020 to January 1, 2021, state-level estimates of R_t ranged
128 from 0.6 (0.5, 0.8) to 1.7 (1.4, 2.0) (Figure 4).

129 **Figure 4:** R_t estimates for each US state from March 1, 2020 to January 1, 2021.
130 Background colors indicate whether R_t is substantially greater than 1 (red), close to 1
131 (white), or substantially less than 1 (blue). Grey line indicates $R_t = 1$. Shaded areas
132 represent 95% credible intervals.

133 *Percent Ever-Infected with SARS-CoV-2*

134 For each county, we calculated the percentage of the population ever-infected as the sum of all
135 estimated infections divided by county population on January 1, 2021 (Figure 5). This
136 cumulative infection estimate is distinct from reported seroprevalence estimates, as
137 seroprevalence measures may be affected by the lower immune response among individuals with
138 mild/asymptomatic infection, possible waning of antibody titers,^{11,12} and non-representativeness
139 of sampled populations.¹³ By January 1 2021, we found that the percent of the population ever-
140 infected exceeded 50% in 241 (7.7%) counties and exceeded two-thirds of the population in 22
141 (0.7%) counties. Conversely, the percent ever-infected was less than 10% in 145 (4.6%) counties
142 and less than 5% in 34 (1.1%) counties. Based on the sum of state estimates (posterior medians),
143 we estimate that 27% of the US population had been infected with SARS-CoV-2 by January 1,
144 2021. Across states, the percent ever-infected ranged from 6.7% (4.4%, 10.9%) in Vermont to in
145 44.6% (30.0%, 66.5%) Arizona (Figure 3).

146 On January 1, 2021, the US had reported 349,247 cumulative COVID-19 deaths.¹⁴ Based on the
147 sum of state estimates (posterior medians), we estimate there were 400,718 cumulative COVID-
148 19 deaths as of January 1, 2021, 14.7% greater than cumulative reported deaths and
149 approximately 0.12% of the US population on January 1, 2020. Estimates of the size of the

150 infected population were sensitive to assumptions about the infection fatality rate, with higher
151 IFR values producing lower estimates of the infected population (Figure S1).

152 **Figure 5:** Percentage of the population ever-infected with SARS-CoV-2 as of January 1,
153 2021.

154 *Case Ascertainment*

155 The probability that an infection is diagnosed changed substantially over the course of the U.S.
156 epidemic. Ascertainment was low in the months of March, April, and May 2020. The national
157 median state-level case ascertainment (based on state-level posterior medians) in this period was
158 14% (range: 3.8%, 41.2%). Infection ascertainment improved steadily through June 2020 before
159 plateauing; the national mean probability of diagnosis fluctuated between 24% and 37% between
160 July 1, 2020 and January 1, 2021. Infection ascertainment estimates varied significantly across
161 states, and state-level estimates were highly uncertain (Figure 6). Only 5 states achieved greater
162 than 50% ascertainment at any point in time (based on posterior median). State-level model
163 estimates of infection ascertainment each day are very weakly correlated with the seven-day
164 moving average fraction of tests that have a positive result (Spearman rank correlation (ρ) = -
165 0.10, $p < 0.001$). From the introduction of SARS-CoV-2 in the US until January 1, 2021, we
166 estimate that 22.9% of infections were identified and reported.

167 **Figure 6:** The probability that a person infected with SARS-CoV-2 on a given day will
168 be diagnosed for each US state from March 1, 2020 to January 1, 2021. Shaded areas
169 represent 95% credible intervals.

170 **Comparisons to External Covid-19 Burden Indicators**

171 We compared our estimates of the percent ever-infected with SARS-CoV-2 to U.S. Centers for
172 Disease Control (CDC) seroprevalence estimates drawn from commercial laboratory data,¹⁵
173 acknowledging previously noted differences between these different outcomes. Derived from a
174 convenience sample of blood specimens collected for reasons unrelated to COVID-19, the
175 seroprevalence estimates provide state-level evidence on SARS-CoV-2 antibody test positivity at
176 multiple time points (Figure 7). However, these estimates are incomplete in some states (e.g.
177 South Dakota), and the series of values declines over time in others (e.g. New York). Comparing
178 these estimates to other reported indicators of cumulative disease burden on January 1 2021, the
179 modeled estimates of the percent ever-infected were more strongly correlated with cumulative
180 hospitalizations (Spearman rank correlation (ρ) = 0.60) and cumulative reported deaths (ρ =
181 0.81) than the CDC seroprevalence estimates (ρ = 0.41 and 0.37 for hospitalizations and deaths
182 respectively).

183 **Figure 7:** Comparison of the estimated percent ever-infected with SARS-CoV-2 (purple
184 line, shaded areas represent 95% credible intervals) to CDC seroprevalence estimates
185 from commercial laboratory data (red vertical line) and cumulative reported cases (black
186 line) for each US state from March 1, 2020 to January 1, 2021.

187 In addition, we compared model estimates of cumulative COVID-19 deaths (detected and
188 undetected) to state-level estimates of excess all-cause mortality, which reflect both COVID-19
189 deaths and deviations from expected levels and patterns in non-COVID-19 deaths,⁶ (Figure 8) at
190 each weekly timepoint from March 7 to December 19, 2020. On average, modeled estimates of
191 cumulative COVID-19 deaths are less than or approximately equal to estimates of excess all-
192 cause mortality. Notably, three states (Alaska, Hawaii, Maine) have extended periods where the
193 estimated all-cause mortality did not exceed all-cause mortality from previous years (i.e. excess

194 mortality was negative); in periods where all-cause mortality is higher than expected, our
195 estimates of COVID-19 deaths correlate strongly with excess mortality estimates (Spearman
196 rank correlation (ρ) = 0.96, $p < 0.001$). Additionally, model estimates of cumulative COVID-19
197 deaths exceed estimates of excess all-cause mortality in two states (Massachusetts and Rhode
198 Island). Estimates of excess all-cause mortality were not available for Connecticut, North
199 Carolina, or West Virginia.

200 **Figure 8:** Comparison of cumulative COVID-19 deaths (blue) to cumulative excess all-
201 cause mortality (red) for each US state from March 7 to December 19, 2020. Shaded
202 areas represent 95% credible intervals.

203 Discussion

204 We present detailed estimates of the dynamics of SARS-CoV-2 infections in US states and
205 counties through the end of 2020. We found that the viral dynamics are best described as a series
206 of related local and regional epidemics, differing in their timing and magnitude even within
207 individual states. This is evident in the large variation in state- and county-level estimates of
208 percent ever-infected as of January 1, 2021. As case ascertainment has also varied over space
209 and time, these estimates provide insights beyond those that can be inferred from cumulative
210 case counts alone. Ascertainment of infection improved markedly after the first months of the
211 US epidemic, but remained low nationally; we conclude that the reported cumulative case count
212 was approximately one-quarter of the true number of US infections at the end of 2020.

213 Most notably, we found that model estimates of cumulative infections differ from seroprevalence
214 estimates produce by the CDC. We note that our estimates of cumulative infections are more
215 strongly correlated with cumulative hospitalizations and deaths across states, potentially

216 reflecting biases in the empirical seroprevalence estimates. Seroprevalence studies have a
217 number of known limitations, including the use of non-representative samples¹³ and possible
218 reduced sensitivity associated with waning of antibody titers, as has been reported for some
219 tests.^{11,12} A comparison between model estimates and seroprevalence data therefore suggests that
220 this method provides valuable information about the incidence of infection over time.

221 The Bayesian estimation approach used for this analysis makes a number of simplifying
222 assumptions. To reduce model complexity, we rely on fixed distributions to describe delays in
223 disease progression and detection. Because we anchor the analysis on death data (under the
224 assumption that deaths were more consistently reported than cases over the course of the
225 epidemic), model estimates are sensitive to infection fatality risk (IFR) estimates, which are
226 themselves uncertain. Finally, we assume that a previously infected individual cannot be re-
227 infected with SARS-CoV-2. While waning antibody titers suggest that re-infection is possible
228 over time, we do not believe that our assumptions about re-infection meaningfully impact our
229 results.^{16,17}

230 In addition, we used data that have been aggregated from state-level reporting mechanisms,
231 which are vulnerable to a number of potential sources of bias. States vary in their reporting
232 criteria (e.g. reporting the number of positive tests as opposed to number of individuals who have
233 tested positive) and the average delay between case detection and reporting. Data are also subject
234 to occasional revisions, often implemented as a single-day change in the cumulative count of
235 cases or deaths. Taken together, these data irregularities lead to additional variance in the
236 reported data and a reduction in the precision of reported estimates. While line-list data would
237 likely improve the precision of model estimate¹⁸, these data are not widely available in the US,
238 and it is not possible to generate the results presented here from a method which relies solely on

239 line-list data. Despite these limitations, the method described here may represent an
240 improvement over similar modeling approaches that do not allow for case ascertainment rates
241 and infection fatality ratios that vary over both space and time,^{8,9,19,20} or that estimate R_t using
242 model outputs rather than as part of the modeling framework.^{9,18,20} Furthermore, our approach
243 uses changes in case and death data to estimate changes in transmission, while others approaches
244 make use of more indirect data on mobility^{8,19} or similar proxies²⁰ to signal changes in
245 transmission. While mobility has a mechanistic relationship with disease transmission, the
246 association between movement data and viral transmission is complex, possibly because of
247 changes in mask use and other non-pharmaceutical interventions, and was an increasingly poor
248 predictor of transmission as the epidemic progressed in the US.^{21,22}

249 In conclusion, the modeling approach described here provides a coherent framework for
250 simultaneously estimating the trend in SARS-CoV-2 infections and the fraction of the population
251 that has been infected previously, providing key information on the viral dynamics at county-
252 and state-levels. While the deployment of effective vaccines against the virus represents a great
253 hope for the control of SARS-CoV-2 transmission, vaccine hesitancy and the emergence of more
254 transmissible variants²³ present an ongoing challenge to disease control in the US. Understanding
255 the course of the epidemic in the pre-vaccine era can help guide decision making in a landscape
256 with heterogenous vaccine coverage. Ongoing, local evidence on trends in R_t and new and
257 cumulative infections will continue to be important for both governments and individuals.

258 **Methods**

259 We developed a mechanistic model that uses reported case and death data to back-calculate the
260 natural history cascade of SARS-CoV-2. The model estimates the expected number of cases and

261 deaths reported on a given day as the convolution of the time series of diagnosed cases and
262 deaths (among diagnosed individuals) and fixed reporting delay distributions; the expected
263 number of diagnoses on a given day is estimated with health-state specific and time-varying
264 probabilities of diagnosis. The model represents the natural history of COVID-19 as a series of
265 health state transitions with associated probabilities and delays (Figure 1). The model utilizes
266 delay distributions associated with health state progression, time-invariant probabilities of
267 transitioning from *Asymptomatic* to *Symptomatic* and from *Symptomatic* to *Severe*, and a time-
268 varying probability of transitioning from *Severe* to *Death*. The number of individuals entering
269 *Asymptomatic* is a function of the serial interval, the fraction of the population not yet infected,
270 and R_t ; R_t is modeled using a log-transformed cubic b-spline.

271 **Data**

272 For every state and county in the United States, we extracted daily data on reported COVID-19
273 cases and deaths from a repository compiled by the Johns Hopkins Center for Systems Science
274 and Engineering (CSSE)⁹. We calculated the time series of new cases and deaths as the
275 difference between cumulative counts reported on consecutive days. In instances in which the
276 reported cumulative count decreased from one day to the next, we assumed that there were zero
277 new cases or deaths on each day until the cumulative count exceeded the previous maximum. In
278 several instances the data reported by CSSE fail to capture the beginning of the epidemic in early
279 2020, or exhibit irregularities during this period. To reconstruct the time series for this period we
280 used data compiled by the Covid Tracking Project.²⁴

281 **Mathematical model**

282 We constructed a deterministic mathematical model relating reported cases and deaths to
283 unobserved COVID-19 natural history. A flexible function for R_t determines the number of
284 individuals infected on a given day, and the model then tracks the progression of the infected
285 cohort through health states of increasing disease severity, with modelled quantities— A_t
286 (*Asymptomatic*), S_t (*Symptomatic*), V_t (*Severe*), and D_t (*Death*)—reflecting the number of
287 individuals entering a given health state on day t . From each health state, an individual can either
288 recover or progress to the next health state, with this transition governed by a defined delay
289 distribution. Ultimately, the model estimates an expected number of reported cases and deaths on
290 each day, which are fit to observed data via negative binomial likelihood functions.

291 *New infections*

292 We modelled the daily number of newly-infected individuals (A_t) entering the *Asymptomatic*
293 state. For each modelled location, we specified a random intercept (A_0) 28 days before the first
294 reported COVID-19 case, and calculated changes in A_t as a function of the effective
295 reproduction number (R_t) and the serial interval (z), measured in days.

$$296 \quad A_{t+1} = A_t R_t^{\frac{1}{z}} \quad \text{for } t \geq 0 \quad [1]$$

297 We modelled the time trend in R_t using a log-transformed cubic b-spline ($X_{R,t}$) with knots every
298 5 days, allowing flexibility in the evolution of the epidemic curve over time. Penalties on first
299 and second differences of the spline parameters were used to dampen oscillations not supported
300 by the data. We assumed that individuals can only be infected once and multiplied the spline by
301 the fraction of the population (N) uninfected at each timepoint, penalizing R_t towards zero as the
302 population ever-infected approaches 100%.

303
$$R_t = X_{R,t} \left(1 - \frac{\sum_{i=0}^t A_i}{N} \right)$$
 [2]

304 *Disease progression*

305 We assumed that a fraction of individuals with asymptomatic disease (p_S) progress to the
306 *Symptomatic* state. The delay from infection to symptoms was assumed to follow a Gamma
307 distribution, with $\rho_{S,i}$ representing the fraction progressing between i and $i+1$ days after
308 infection, among those progressing to the symptomatic state.

309
$$S_t = \sum_{i=0}^t A_{t-i} p_S \rho_{S,i}$$
 [3]

310 Similarly, a fraction of individuals in the *Symptomatic* state (p_V) were assumed to progress to the
311 *Severe* state, with Gamma-distributed delay distribution $\rho_{V,i}$. A fraction of individuals with
312 severe disease ($p_{D,t}$) die, with Gamma-distributed delay distribution $\rho_{D,i}$.

313
$$V_t = \sum_{i=0}^t S_{t-i} p_V \rho_{V,i}$$
 [4]

314
$$D_t = \sum_{i=0}^t V_{t-i} p_{D,t} \rho_{D,i}$$
 [5]

315 With the exception of $p_{D,t}$, disease progression parameters were not allowed to vary over time.
316 For $p_{D,t}$ we assumed higher values applied in early 2020, reflecting higher case fatality among
317 individuals with severe disease early in the epidemic due to later presentation and lower
318 effectiveness of treatment at that time. We modeled the time trend in $p_{D,t}$ as a sigmoid curve
319 (operationalized using the Normal cumulative distribution function Φ) with an inflection point
320 on May 1 2020. The odds ratio OR_{p_D} describes the elevated case fatality early in the epidemic,

321 and p_{D0} defines the progression probability after early 2020. In Equation 6, μ is equal to the
322 number of days between the start of the model ($t=0$) and May 1st 2020, and σ is equal to 21 days.

$$323 \quad \frac{p_{D,t}}{1-p_{D,t}} = \frac{p_{D,0}}{1-p_{D,0}} \left(1 + \Phi \left(\frac{\mu-t}{\sigma} \right) OR_{p_D} \right) \quad [6]$$

324 While vaccination would also affect disease progression probabilities, we assumed that
325 vaccination coverage was insufficient to impact disease natural history during the study period.

326 *Infection fatality ratio*

327 We assumed that the infection fatality ratio (IFR) differs across states and counties, reflecting
328 differences in the age distribution of the epidemic and differences in the prevalence of medical
329 risk factors for severe COVID-19 disease. First, we calculated the age distribution of infections
330 for each state, based on the reported age distribution of COVID-19 deaths²⁵ and published age-
331 specific IFRs.²⁶ Second, we used these age distributions to calculate an average IFR for each
332 state, weighting the age-specific IFRs by the fraction of the population in each age group. This
333 produced a national average IFR of 0.35, which we believe to be implausibly low; we rescaled
334 state-level values to produce a national average IFR of 0.5%.²⁷ As the age-distribution of
335 COVID-19 deaths was not available at the county-level, we estimated county-level IFR values
336 by multiplying the state-average IFR by the prevalence of medical risk factors for severe
337 COVID-19 disease in each county relative to the rest of the state.²⁸ To understand the
338 implications uncertainty in the IFR for modelled estimates of the infected population, we plotted
339 the relationship between these two quantities in the fitted model outcomes.

340 *Diagnosis*

341 We assumed that infected individuals could be diagnosed from the *Asymptomatic*, *Symptomatic*,
342 or *Severe* states, and that diagnosis would not affect disease progression. We assumed that
343 diagnosis in the *Asymptomatic* state only occurs among individuals who will not progress to the
344 *Symptomatic* state. The daily number of these diagnoses is denoted \hat{A}_t (with the \wedge used to
345 indicate quantities related to diagnosis). The fraction of these individuals diagnosed ($q_{A,t}$) was
346 assumed to vary over time, to allow for changes in case ascertainment over the course of the
347 epidemic. The delay to diagnosis was defined by $\hat{\rho}_{A,i}$, which is described by a Gamma
348 distribution.

$$349 \quad \hat{A}_t = \sum_{i=0}^t A_{t-i} q_{A,t-i} \hat{\rho}_{A,i} (1 - p_S) \quad [7]$$

350 To estimate the number diagnosed from the *Symptomatic* state (\hat{S}_t) we assumed a time-varying
351 probability of diagnosis $q_{S,t}$ and delay to diagnosis $\hat{\rho}_{S,i}$.

$$352 \quad \hat{S}_t = \sum_{i=0}^t S_{t-i} q_{S,t-i} \hat{\rho}_{S,i} \quad [8]$$

353 The number diagnosed from the *Severe* state (\hat{V}_t), was calculated based on a time-invariant
354 probability of diagnosis (q_V) and delay to diagnosis $\hat{\rho}_{V,i}$. These were applied after subtracting
355 individuals developing severe disease who had been previously diagnosed at *Symptomatic* (\bar{V}_t).

$$356 \quad \bar{V}_t = \sum_{i=0}^t S_{t-i} q_{S,t-i} p_V \rho_{V,i} \quad [9]$$

$$357 \quad \hat{V}_t = \sum_{i=0}^t (V_{t-i} - \bar{V}_{t-i}) q_V \hat{\rho}_{V,i} \quad [10]$$

358 Time-varying diagnosis probabilities ($q_{A,t}$, $q_{S,t}$) were calculated as a function of q_V :

$$359 \quad q_{S,t} = q_V X_{q_{S,t}} \quad [11]$$

$$360 \quad q_{A,t} = q_V X_{q_S,t} RR_{q_A} \quad [12]$$

361 In equations 11 and 12, $X_{q_S,t}$ is a logit-transformed cubic b-spline with knots spaced 21 days
 362 apart, with penalties on first and second differences of the spline parameters. RR_{q_A} is constrained
 363 to fall in the unit interval, so that that $q_{A,t} \leq q_{S,t} \leq q_V$ for all t .

364 *Reporting*

365 We assumed that all diagnosed COVID-19 cases were reported. The number of diagnoses
 366 reported on a given day (\dot{C}_t , with the ‘ \cdot ’ used to indicate quantities related to reporting) was
 367 calculated as the sum of diagnoses from *Asymptomatic*, *Symptomatic* and *Severe* states, with
 368 reporting delay $\dot{\rho}_{C,i}$.

$$369 \quad \dot{C}_t = \sum_{i=0}^t (\hat{A}_{t-i} + \hat{S}_{t-i} + \hat{V}_{t-i}) \dot{\rho}_{C,i} \quad [13]$$

370 The reported number of COVID-19 deaths (\dot{D}_t) were calculated from the number of diagnosed
 371 individuals who subsequently died (\hat{D}_t). \hat{D}_t was calculated as the sum of deaths among
 372 individuals diagnosed from the *Symptomatic* and *Severe* states, represented by the first and
 373 second terms in equation 14, respectively. We assumed that all deaths among diagnosed COVID-
 374 19 cases were reported, with reporting delay $\dot{\rho}_{D,i}$.

$$375 \quad \hat{D}_t = \left(\sum_{i=0}^t \bar{V}_{t-i} p_{D,t} \rho_{D,i} \right) + \left(\sum_{i=0}^t (V_{t-i} - \bar{V}_{t-i}) q_V p_{D,t} \rho_{D,i} \right) \quad [14]$$

$$376 \quad \dot{D}_t = \sum_{i=0}^t \hat{D}_{t-i} \dot{\rho}_{D,i} \quad [15]$$

377 **Data likelihood**

378 We specified negative binomial likelihood functions to fit the model to observed cases ($Y_{C,t}$) and
 379 death data ($Y_{D,t}$).

$$Y_{C,t} \sim NegBin(\hat{C}_t, \phi_C)$$

$$Y_{D,t} \sim NegBin(\hat{D}_t, \phi_D)$$

380 To account for variation in daily reported cases and deaths, we implemented the likelihood using
 381 a seven-day moving average of input data and modeled values. The negative binomial dispersion
 382 parameters (ϕ_C, ϕ_D) were estimated simultaneously, allowing for additional variance in the
 383 observed time series.

384 **Model parameters**

385 Model parameters are shown in Table 1.

386 **Table 1:** Model parameters

Model Parameter	Mean, std. Deviation	Distribution	Type	Source
Log Of New Infections At T=0 (A_0)	0,10	Normal(0,10)	prior	Assumed
$X_{R,t}$ Spline Parameters	0,3	Normal(0,3)	prior	Assumed
First Derivative of $X_{R,t}$ Spline Parameters	0,0.5	Normal(0,0.5)	prior	Assumed
Second Derivative of $X_{R,t}$ Spline Parameters	0,0.1	Normal(0,0.1)	prior	Assumed
Serial Interval	5.8, 0.5	Gamma(129.1, 22.25)	prior	29
Probability of Developing Symptoms If Infected	0.59, 0.16	Beta(5.14, 3.53)	prior	30-33
Probability of Becoming Severely Ill If Symptomatic	0.09, 0.06	Beta(1.89, 20.00)	prior	35
Probability of Death for All Infections (national average)	0.005, 0.001	Beta(15.9, 3167)	prior	26,27
Probability of Death for Severe Infections	0.15, 0.03	Beta(28.2, 162.3)	prior	35

Rate Ratio, Diagnosis at Asymptomatic Vs. Symptomatic	0.1, 0.07	Beta(2,18)	prior	Assumed
Rate Ratio, Diagnosis at Symptomatic Vs. Severe	0.5, 0.22	Beta(2,2)	prior	Assumed
Probability of Diagnosis at Severe	0.72, 0.16	Beta(20,5)	prior	Assumed
Case Dispersion Parameter $(1/\sigma)^2$ *	0.8, 0.6	Half-Normal(0,1)	prior	36
Death Dispersion Parameter $(1/\sigma)^2$ *	0.8, 0.6	Half-Normal(0,1)	prior	36
Time from Infected to Symptomatic (Days)	5.6, 3.1	Gamma(3.41, 0.61)	fixed	37
Time from Symptomatic to Severe (Days)	7.5, 5.8	Gamma(1.72, 0.22)	fixed	38
Time from Severe to Death (Days)	9.1, 6.3	Gamma(2.10, 0.23)	fixed	39
Scaling Factor: Time to Diagnosis Relative to Time in Symptomatic State	0.5, 0.22	Beta(2,2)	prior	Assumed
Scaling Factor: Time to Diagnosis Relative to Time in Severe State	0.5, 0.22	Beta(2,2)	prior	Assumed
Case Reporting Delay	2.2, 1.5	Gamma(2.2, 1)	prior	Assumed
Death Reporting Delay	2.2, 1.5	Gamma(2.2, 1)	prior	Assumed

387

388 **Model implementation**

389 The model was implemented in R using the rstan package.⁴⁰ The model initializes 28 days before
 390 the first reported case or death. Given the delay from infection to death, we chose 28 days to
 391 allow the model to generate the necessary number of new infections to plausibly result in a death
 392 early in the observed time series. The model is fit to data from each county or state separately.
 393 For state-level results we estimated outcomes using a Hamiltonian Monte Carlo algorithm.⁴¹ The
 394 model ran for 3000 iterations (2000 burn-in) on 5 chains, and 4000 samples (across 4 chains)
 395 from the posterior were included in these results. Counties were fit using an optimization routine
 396 that reports the maximum a posteriori estimate, which represents an estimate of the mode of the
 397 posterior distribution of the model parameters.

398 **covidestim Package**

399 The *covidestim* package is a package for the R programming language, suitable for public as well
400 as research use. It can accommodate a number of data inputs. Users may enter a vector of daily
401 case counts and/or daily death counts. These data sources can be used in combination, so long as
402 they are the same length and cover the same time period; days with no observed events may be
403 represented with zeroes.

404 The package contains default model priors for progression probabilities and delays, detection
405 probabilities and delays, and reporting delays associated with each data type. Users have the
406 ability to override these defaults, though we recommend that they only specify priors for
407 reporting delays; we do not recommend that users change default priors on parameters related to
408 the natural history of COVID-19.

409 **Covidestim.org and code repositories**

410 We produce daily estimates of COVID-19 infections and the effective reproduction number of
411 SARS-CoV-2 at the state- and county-levels at <https://covidestim.org>. To allow for daily
412 production of model estimates for all U.S. counties and states, we developed several tools. The
413 *covidestim* Docker image is a container which allows for model execution in any HPC or cloud
414 environment, and is the easiest way to begin using the *covidestim* R package. The *covidestim-*
415 *sources* repository enables automated, version-controlled, reproducible data cleaning of four
416 different case/death data sources by leveraging Git's submodules feature. Finally, the *dailyFlow*
417 repository uses the Nextflow workflow engine⁴² to clean the data, orchestrate 3200+ model runs
418 within three supported execution environments (local, HPC, cloud), and export the results for
419 research use and for web consumption. These repositories can be found at
420 <https://github.com/covidestim>, and contain extensive documentation.

421 **Acknowledgments:** We thank Jeffrey Eaton for his thoughts on statistical analysis.

422

423

References

- 424 1. Coronavirus in the U.S.: Latest Map and Case Count. Retrieved from
425 <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>
- 426 2. Coronavirus. Retrieved from
427 [https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-](https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=hp_pandemic%20test)
428 [deaths/?itid=hp_pandemic%20test](https://www.washingtonpost.com/graphics/2020/national/coronavirus-us-cases-deaths/?itid=hp_pandemic%20test)
- 429 3. Oran DP and Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative
430 review. *Annals of internal medicine*. 2020; 173(5): 362-367.
- 431 4. Hitchings MDT, Dean NE, Garcia-Carreras B, Hladish TJ, Huang AT, Yang B, Cummings
432 DAT. The Usefulness Of SARS-CoV-2 Test-Positive Proportion As A Surveillance Tool.
433 *American Journal of Epidemiology*. 2021; 190(7):1396–1405.
434 <https://doi.org/10.1093/aje/kwab023>
- 435 5. Pitzer VE, Chitwood MH, Havumaki J, Menzies NA, Perniciaro S, Warren JL, et al. The
436 impact of changes in diagnostic testing practices on estimates of COVID-19 transmission in
437 the United States. *American Journal of Epidemiology*. 2021;
438 <https://doi.org/10.1093/aje/kwab089>
- 439 6. Weinberger D, Cohen T, Crawford F, Mostashari F, Olson D, Pitzer VE, et al., Estimating
440 the early death toll of COVID-19 in the United States. [Preprint]. 2020 [Cited 2020 July 13]
441 Available from: <https://doi.org/10.1101/2020.04.15.20066431>.
- 442 7. Gostic KM, McGough L, Baskerville E, Abbott S, Joshi K, Tedijanto C, et al. Practical
443 considerations for measuring the effective reproductive number, Rt. *PLoS Comput. Biol.*
444 2021; 16(12): e1008409. <https://doi.org/10.1371/journal.pcbi.1008409>
- 445 8. Unwin HJT, Mishra S, Bradley VC, Gandy A, Mellan TA, Coupland H, et al. State-level
446 tracking of COVID-19 in the United States. *Nat. Commun.* 2020; 11, 6189
447 <https://doi.org/10.1038/s41467-020-19652-6>
- 448 9. COVID-19 Portal, Center for the Ecology of Infection Diseases, University of Georgia [Cited
449 2021 July 10]. Available at: <https://www.covid19.uga.edu/nowcast.html>
- 450 10. Considerations for implementing and adjusting public health and social measures in the
451 context of COVID-19. Geneva: World Health Organization;
452 [https://apps.who.int/iris/bitstream/handle/10665/336374/WHO-2019-nCoV-](https://apps.who.int/iris/bitstream/handle/10665/336374/WHO-2019-nCoV-Adjusting_PH_measures-2020.2-eng.pdf?sequence=1&isAllowed=y)
453 [Adjusting PH measures-2020.2-eng.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/336374/WHO-2019-nCoV-Adjusting_PH_measures-2020.2-eng.pdf?sequence=1&isAllowed=y)
- 454 11. Ibarrodo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofmann C, Hausner MA, et al. Rapid
455 Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *N Engl J Med.*
456 2020; 383:1085-1087. DOI: 10.1056/NEJMc2025179
- 457 12. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA. Longitudinal observation
458 and decline of neutralizing antibody responses in the three months following SARS-CoV-2
459 infection in humans. *Nat Microbiol.* 2020; 5:1598–1607 [https://doi.org/10.1038/s41564-020-](https://doi.org/10.1038/s41564-020-00813-8)
460 [00813-8](https://doi.org/10.1038/s41564-020-00813-8)
- 461 13. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T. Estimated SARS-CoV-2
462 Seroprevalence in the US as of September 2020. *JAMA Intern Med.* November 24, 2020;
463 doi:10.1001/jamainternmed.2020.7976
- 464 14. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
465 time. *Lancet Inf. Dis.* May 1, 2020; 20(5):533-534. DOI: [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30120-1)
466 [3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)

- 467 15. Nationwide Commercial Laboratory Seroprevalence Survey. [Cited 23 March, 2020]
468 Available at: [https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-](https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-Laboratory-Seroprevalence-Su/d2tw-32xv)
469 [Laboratory-Seroprevalence-Su/d2tw-32xv](https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-Laboratory-Seroprevalence-Su/d2tw-32xv)
- 470 16. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M. Robust neutralizing
471 antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020; 370(6521):1227-
472 1230. doi: 10.1126/science.abd7728.
- 473 17. Qureshi AI, Baskett WI, Huang W, Lobanova I, Naqvi SH, Shyu C. Reinfection with Severe
474 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial
475 Laboratory Testing. *Clinical Infectious Diseases*. 2021; <https://doi.org/10.1093/cid/ciab345>
- 476 18. Li T, White LF. Bayesian back-calculation and nowcasting for line list data during the
477 COVID-19 pandemic. *PLOS Computational Biology*. 2021; 17(7): e1009210.
478 <https://doi.org/10.1371/journal.pcbi.1009210>
- 479 19. Flaxman S, Mishra S, Gandy A, Unwin JT, Mellan TA, Coupland H, et al. Estimating the
480 effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. 2020; 584:
481 257–261 <https://doi.org/10.1038/s41586-020-2405-7>
- 482 20. Leung K, Wu JT & Leung GM. Real-time tracking and prediction of COVID-19 infection
483 using digital proxies of population mobility and mixing. *Nat Commun*. 2021; 12: 1501
484 <https://doi.org/10.1038/s41467-021-21776-2>
- 485 21. Kishore N, Taylor AR, Jacob PE, Vembar N, Cohen T, Buckee CO, et al. The relationship
486 between human mobility measures and SAR-CoV-2 transmission varies by epidemic phase
487 and urbanicity: results from the United States. [Preprint] 2021. [Cited 15 July 2021].
488 Available from: <https://www.medrxiv.org/content/10.1101/2021.04.15.21255562v1>
- 489 22. Nouvellet P, Bhatia S, Cori A, Ainslie KEC, Baguelin M, Bhatt S, et al. Reduction in
490 mobility and COVID-19 transmission. *Nat Commun*. 2021; 12: 1090
491 <https://doi.org/10.1038/s41467-021-21358-2>
- 492 23. COVID Data Tracker. “Variant Proportions” [Cited 8 June 2021] Available at:
493 <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>
- 494 24. The COVID Tracking Project. [Cited 15 January 2021] Available at:
495 <https://covidtracking.com/>
- 496 25. National Center for Health Statistics. “Provisional COVID-19 Death Counts by Sex, Age,
497 and State” [Cited 15 January 2021] Available at: [https://data.cdc.gov/NCHS/Provisional-](https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku)
498 [COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku](https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku)
- 499 26. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al.
500 Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*. 2021; 590; 140–145
501 <https://doi.org/10.1038/s41586-020-2918-0>
- 502 27. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G.
503 Assessing the age specificity of infection fatality rates for COVID-19: systematic review,
504 meta-analysis, and public policy implications. *Eur J Epidemiol*. 2020; 35: 1123–1138.
505 <https://doi.org/10.1007/s10654-020-00698-1>
- 506 28. Razzaghi H, Wang Y, Lu H, et al. Estimated County-Level Prevalence of Selected
507 Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19
508 Illness — United States, 2018. *MMWR Morb Mortal Wkly Rep* 2020;69:945–950. DOI:
509 <http://dx.doi.org/10.15585/mmwr.mm6929a1>
- 510 29. X He, EH Lau, P Wu, Marshall KE, Dowling NF, Paz-Bailey G, et al. Temporal dynamics in
511 viral shedding and transmissibility of COVID-19. *Nature medicine*. 2020; 26(5): pp.672-675.

- 512 30. Poletti, P., Tirani, M., Cereda, D., Trentini, F., Guzzetta, G., Sabatino, G., Marziano, V.,
513 Castrofino, A., Grosso, F., Del Castillo, G. and Piccarreta, R., 2020. Probability of symptoms
514 and critical disease after SARS-CoV-2 infection. arXiv preprint arXiv:2006.08471.
515 31. Oran, D.P. and Topol, E.J., 2020. Prevalence of asymptomatic SARS-CoV-2 infection: a
516 narrative review. *Annals of internal medicine*, 173(5), pp.362-367.
517 32. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.
518 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2
519 infections: A living systematic review and meta-analysis. *PLOS Medicine*. 2020; 17(9):
520 e1003346. <https://doi.org/10.1371/journal.pmed.1003346>
521 33. O Byambasuren, M Cardona, K Bell, J Clark, M McLaws, P Glasziou (2020). “Estimating
522 the extent of asymptomatic COVID-19 and its potential for community transmission:
523 systematic review and meta-analysis.” *JAMMI*. 5(4): 223-234.
524 <https://doi.org/10.3138/jammi-2020-0030>
525 34. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
526 severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious*
527 Diseases. 2020; 20(6): 669 – 677.
528 35. CDC COVID-19 Response Team. “Severe Outcomes Among Patients with Coronavirus
529 Disease 2019 (COVID-19) — United States, February 12–March 16, 2020.” *MMWR*.
530 *Morbidity and Mortality Weekly Report* (2020) 69(12), 343--346. ISSN 0149-2195, 1545-
531 861X, doi: [10.15585/mmwr.mm6912e2](https://doi.org/10.15585/mmwr.mm6912e2)
532 36. Gelman, A. Prior Choice Recommendations. Github. 2020 April 17 [Cited 2021 July 10].
533 Available from: <https://github.com/stan-dev/stan/wiki/Prior-Choice-Recommendations>
534 37. SA Lauer, KH Grantz, Q Bi, et al. “The Incubation Period of Coronavirus Disease 2019
535 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.” *Annals*
536 *of Internal Medicine* (2020). 172(9), 577--582. ISSN 0003-4819, 1539-3704, doi:
537 [10.7326/M20-0504](https://doi.org/10.7326/M20-0504)
538 38. F Zhou, T Yu, R Du, et al. “Clinical course and risk factors for mortality of adult inpatients
539 with COVID-19 in Wuhan, China: a retrospective cohort study.” *The Lancet*. (2020).
540 395(10229), 1054--1062. ISSN 01406736, doi: [10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
541 39. NM Linton, T Kobayashi, Y Yang, K Hayashi, AR Akhmetzhanov, S Jung, B Yuan, R
542 Kinoshita, H Nishiura. “Incubation Period and Other Epidemiological Characteristics of 2019
543 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly
544 Available Case Data.” *Journal of Clinical Medicine*. (2020). 9(2), 538. ISSN 2077-0383, doi:
545 [10.3390/jcm9020538](https://doi.org/10.3390/jcm9020538)
546 40. Stan Development Team. RStan: the R interface to Stan. 2018 R package version 2.17.3.
547 <http://mc-stan.org>
548 41. Hoffman MD and Gelman A. The No-U-Turn sampler: adaptively setting path lengths in
549 Hamiltonian Monte Carlo. *J Mach Learn Res*. 2012; 15(1): 1593-1623.
550 42. Di Tommaso P, Chatzou M, Floden E, Barja PP, Palumbo E, Noterdame C. Nextflow enables
551 reproducible computational workflows. *Nat Biotechnol*. 2017; 35, 316–319.
552 <https://doi.org/10.1038/nbt.3820>
553

554 **Funding:**

555 KG reports grant from National Institutes of Health T32 GM007205 and Fogarty International
556 Center D43 TW010540

557 VEP reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093


558 DMW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093
559 JLW reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093
560 TC reports grants from National Institute of Allergy and Infectious Diseases R01 AI112438
561 NAM reports grants from National Institute of Allergy and Infectious Diseases R01 AI146555-
562 01A1
563 JAS reports funding from the Centers for Disease Control and Prevention through the Council of
564 State and Territorial Epidemiologists (NU38OT000297-02) and the National Institute on Drug
565 Abuse (3R37DA01561217S1).
566 The funders had no role in study design, data collection and analysis, decision to publish, or
567 preparation of the manuscript.
568

569 **Author contributions:**

570 NAM and TC conceived and supervised the project. NAM and JS acquired funding. MR, KG,
571 and JH curated data. MHC, MR, FK, VEP, JS, JW, DW, TC, and NAM contributed to the
572 development of the methodology. MHC, MR, FK, and NAM wrote the software. MHC, MR, and
573 NAM conducted the formal analysis. MHC, MR, and NS visualized results. Validation was
574 performed by NAM and NS. MHC and NAM drafted the original manuscript. All authors
575 contributed to the review and editing of the original manuscript.
576


577 **Competing interests:** DMW has received consulting fees from Pfizer, Merck, GSK, and
578 Affinivax for topics unrelated to this manuscript and is Principal Investigator on a research grant
579 from Pfizer on an unrelated topic. VEP has received reimbursement from Merck and Pfizer for
580 travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All
581 other authors have declared that no competing interest exist.

582 **Data and materials availability:** All data used in the main analysis are available for use at
583 <https://github.com/covidestim/covidestim-sources>. The *covidestim* package is available for
584 download at <https://github.com/covidestim/covidestim>.




Infections / 100k / day 0 100 200 300 400


1 Apr. 2020




1 May 2020




1 Jun. 2020




1 Jul. 2020




1 Aug. 2020




1 Sept. 2020




1 Oct. 2020





1 Nov. 2020





1 Dec. 2020




1 Jan. 2021











Percent ever infected 0% 20% 40% 60%





Cumulative Deaths per 100,000

